Given after surgery, AZ’s Tagrisso prevents lung cancer coming backAstraZeneca opened its account at this year’ virtual ASCO meeting with data showing that adjuvant (post-surgery) use of Share XGiven after surgery, AZ’s Tagrisso prevents lung cancer coming backhttps://pharmaphorum.com/news/given-after-surgery-azs-tagrisso-prevents-lung-cancer-coming-back/
NICE clears front-line NHS use for Pfizer’s lung cancer drug VizimproPfizer has stolen a march on rival AstraZeneca in the first-line non-small cell lung cancer category, after NICE Share XNICE clears front-line NHS use for Pfizer’s lung cancer drug Vizimprohttps://pharmaphorum.com/news/nice-clears-front-line-nhs-use-for-pfizers-lung-cancer-drug-vizimpro/
